A doctor at a local cancer institute hopes to do more clinical studies to see if lab findings apply to actual patients. Read more at straitstimes.com.

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Nicola Francis has had 20 operations since being born after she was diagnosed with a rare and aggressive tumour after falling ...

Hair loss is a common issue that affects millions of people worldwide causing emotional distress diminished self-esteem and social anxiety Whether due to genetic factors hormonal imbalances medical co ...

Cancer survivor Zoe Plastiras hopes her message provides some reassurance by highlighting advances in cancer treatment.

Recent advances in immunotherapy have revolutionized the treatment of breast and gynecological cancers, and current ...

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2Planned workforce ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive Disease, Beijing ...